BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 26, 2024
See today's BioWorld
Home
» In the clinic
To read the full story,
subscribe
or
sign in
.
In the clinic
Feb. 28, 2017
No Comments
Ligand Pharmaceuticals Inc., of San Diego, said it completed enrollment in its phase II trial testing small-molecule glucagon receptor antagonist LGD-6972 in type 2 diabetes mellitus (T2DM).
BioWorld